1
|
Rudd SE, Van Zuylekom JK, Raicevic A, Pearce LA, Cullinane C, Williams CC, Adams TE, Hicks RJ, Donnelly PS. Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor. Chem Sci 2021; 12:9004-9016. [PMID: 34276928 PMCID: PMC8261882 DOI: 10.1039/d1sc01422f] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Accepted: 05/23/2021] [Indexed: 11/24/2022] Open
Abstract
Identification of tumors which over-express Epidermal Growth Factor Receptor (EGFR) is important in selecting patients for anti-EGFR therapies. Enzymatic bioconjugation was used to introduce positron-emitting radionuclides (89Zr, 64Cu) into an anti-EGFR antibody fragment for Positron Emission Tomography (PET) imaging the same day as injection. A monovalent antibody fragment with high affinity for EGFR was engineered to include a sequence that is recognized by the transpeptidase sortase A. Two different metal chelators, one for 89ZrIV and one for 64CuII, were modified with a N-terminal glycine to enable them to act as substrates in sortase A mediated bioconjugation to the antibody fragment. Both fragments provided high-quality PET images of EGFR positive tumors in a mouse model at 3 hours post-injection, a significant advantage when compared to radiolabeled full antibodies that require several days between injection of the tracer and imaging. The use of enzymatic bioconjugation gives reproducible homogeneous products with the metal complexes selectively installed on the C-terminus of the antibody potentially simplifying regulatory approval.
Collapse
Affiliation(s)
- Stacey E Rudd
- School of Chemistry and Bio21 Molecular Science, Biotechnology Institute University of Melbourne Parkville Victoria 3010 Australia
| | | | - Anna Raicevic
- CSIRO Manufacturing Parkville Victoria 3052 Australia
| | | | - Carleen Cullinane
- Research Division, Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
- Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville Victoria Australia
| | | | | | - Rodney J Hicks
- Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville Victoria Australia
| | - Paul S Donnelly
- School of Chemistry and Bio21 Molecular Science, Biotechnology Institute University of Melbourne Parkville Victoria 3010 Australia
| |
Collapse
|
2
|
Noor A, Van Zuylekom JK, Rudd SE, Roselt PD, Haskali MB, Yan E, Wheatcroft M, Hicks RJ, Cullinane C, Donnelly PS. Imaging Somatostatin Positive Tumors with Tyr 3-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. Bioconjug Chem 2021; 32:1192-1203. [PMID: 33788556 DOI: 10.1021/acs.bioconjchem.1c00109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Radiolabeled derivatives of Tyr3-octreotide and Tyr3-octreotate, synthetic analogues of the peptide hormone somatostatin, can be used for positron emission tomography (PET) imaging of somatostatin receptor expression in neuroendocrine tumors. In this work, a squaramide ester derivative of desferrioxamine B (H3DFOSq) was used attach either Tyr3-octreotide or Tyr3-octreotate to the metal binding ligand to give H3DFOSq-TIDE and H3DFOSq-TATE. These new peptide-H3DFOSq conjugates form stable complexes with either of the positron-emitting radionuclides gallium-68 (t1/2 = 68 min) or zirconium-89 (t1/2 = 3.3 days). The new complexes were evaluated in an AR42J xenograft model that has endogenous expression of SSTR2. All four agents displayed good tumor uptake and produced high-quality PET images. For both radionuclides, the complexes formed with H3DFOSq-TATE performed better, with higher tumor uptake and retention than the complexes formed with H3DFOSq-TIDE. The versatile ligands presented here can be radiolabeled with either gallium-68 or zirconium-89 at room temperature. The long radioactive half-life of zirconium-89 makes distribution of pre-synthesized tracers produced to certified standards feasible and could increase the number of clinical centers that can perform diagnostic PET imaging of neuroendocrine tumors.
Collapse
Affiliation(s)
- Asif Noor
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | | | - Stacey E Rudd
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Peter D Roselt
- Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Mohammad B Haskali
- Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Eddie Yan
- Telix Pharmaceuticals Limited, Suite 401, 55 Flemington Road, North Melbourne, Victoria 3051, Australia
| | - Michael Wheatcroft
- Telix Pharmaceuticals Limited, Suite 401, 55 Flemington Road, North Melbourne, Victoria 3051, Australia
| | - Rodney J Hicks
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Carleen Cullinane
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Paul S Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| |
Collapse
|
3
|
Noor A, Van Zuylekom JK, Rudd SE, Waldeck K, Roselt PD, Haskali MB, Wheatcroft MP, Yan E, Hicks RJ, Cullinane C, Donnelly PS. Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer. J Med Chem 2020; 63:9258-9270. [PMID: 32786229 DOI: 10.1021/acs.jmedchem.0c00291] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Prostate-specific membrane antigen (PSMA) is a carboxypeptidase that is overexpressed in prostate cancer and is an excellent candidate for targeted diagnostic imaging and therapy. Lysine-ureido-glutamate inhibitors of PSMA radiolabeled with positron-emitting radionuclides can be used for diagnostic imaging with positron emission tomography (PET). A squaramide ester derivative of desferrioxamine B (H3DFOSq) was used to prepare four new agents with either one or two lysine-ureido-glutamate pharmacophores. The H3DFOSq ligand can be used to form stable complexes with either of the positron-emitting radionuclides gallium-68 (t1/2 = 68 min) or zirconium-89 (t1/2 = 3.3 days). The complexes were evaluated in PSMA-positive xenograft mouse models. Bivalent inhibitors, where two pharmacophores are tethered to a single DFOSq ligand, have better tumor uptake than their monovalent analogues. The ligands presented here, which can be labeled with either gallium-68 or zirconium-89, have the potential to increase the number of clinical sites that can perform diagnostic PET imaging.
Collapse
Affiliation(s)
- Asif Noor
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | | | - Stacey E Rudd
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Kelly Waldeck
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Peter D Roselt
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Mohammad B Haskali
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Michael P Wheatcroft
- Telix Pharmaceuticals Limited, Suite 401, 55 Flemington Road, North Melbourne, Victoria 3051, Australia
| | - Eddie Yan
- Telix Pharmaceuticals Limited, Suite 401, 55 Flemington Road, North Melbourne, Victoria 3051, Australia
| | - Rodney J Hicks
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia
| | - Carleen Cullinane
- Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia
| | - Paul S Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
| |
Collapse
|
4
|
Noor A, Hayne DJ, Lim S, Van Zuylekom JK, Cullinane C, Roselt PD, McLean CA, White JM, Donnelly PS. Copper Bis(thiosemicarbazonato)-stilbenyl Complexes That Bind to Amyloid-β Plaques. Inorg Chem 2020; 59:11658-11669. [PMID: 32799487 DOI: 10.1021/acs.inorgchem.0c01520] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Alzheimer's disease is characterized by the presence of extracellular amyloid-β plaques. Positron emission tomography (PET) imaging with tracers radiolabeled with positron-emitting radionuclides that bind to amyloid-β plaques can assist in the diagnosis of Alzheimer's disease. With the goal of designing new imaging agents radiolabeled with positron-emitting copper-64 radionuclides that bind to amyloid-β plaques, a family of bis(thiosemicarbazone) ligands with appended substituted stilbenyl functional groups has been prepared. The ligands form charge-neutral and stable complexes with copper(II). The new ligands can be radiolabeled with copper-64 at room temperature. Two lead complexes were demonstrated to bind to amyloid-β plaques present in post-mortem brain tissue from subjects with clinically diagnosed Alzheimer's disease and crossed the blood-brain barrier in mice. The work presented here provides strategies to prepare compounds with radionuclides of copper that can be used for targeted brain PET imaging.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Catriona A McLean
- Department of Anatomical Pathology, The Alfred Hospital, Victoria 3181, Australia
| | | | | |
Collapse
|
5
|
Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS. A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201908964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Nicholas A. Zia
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Carleen Cullinane
- Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne 3010 Vic. Australia
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | | | - Kelly Waldeck
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Lachlan E. McInnes
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Gojko Buncic
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Mohammad B. Haskali
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Peter D. Roselt
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Rodney J. Hicks
- Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne 3010 Vic. Australia
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Paul S. Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| |
Collapse
|
6
|
Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS. A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention. Angew Chem Int Ed Engl 2019; 58:14991-14994. [DOI: 10.1002/anie.201908964] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Indexed: 11/08/2022]
Affiliation(s)
- Nicholas A. Zia
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Carleen Cullinane
- Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne 3010 Vic. Australia
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | | | - Kelly Waldeck
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Lachlan E. McInnes
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Gojko Buncic
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| | - Mohammad B. Haskali
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Peter D. Roselt
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Rodney J. Hicks
- Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne 3010 Vic. Australia
- Research Division Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
- Centre for Cancer Imaging Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia
| | - Paul S. Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute University of Melbourne Melbourne 3010 Vic. Australia
| |
Collapse
|